HIV molecular immunology database
Found 1 matching record:
| HXB2 Location | Gag(180-188) | Gag Epitope Map
View variants at this location |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epitope |
TPQDLNTML
|
Epitope Alignment | ||||||||||||||||
| Variants |
|
|||||||||||||||||
| Epitope Name | TL9, TL9T7 | |||||||||||||||||
| Species (MHC/HLA) | human(B*42:01, B*81:01) | |||||||||||||||||
Showing all: 5 variant(s).
| Variant ID. | 3755 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPQDLNsML |
| Mutations | T/S |
| Epitope Location | T7S |
| HXB2 Location | T186S |
| Mutation Type | A: HLA association OV: observed variant |
| Epitope Subtype | B, C, D, F, G, J, K |
| Variant Subtype | C |
| Method | Other |
| Note | Variant TL9S7, TPQDLNsML, is present in 5% of B*42-/B*81- subjects; 57.1% of B*81+ subjects. Thus T3S substitution is predominantly selected in the presence of B*81. A second substitution at Q3S is observed in association with coexpression of a second TL9 presenting allele, either B*07 or B*42. In 5/6 TL9S7 variant viruses, upstream E177D or downstream T190I/A were seen. Different substitutions at P3 were associated with presence of B*42 allele, where Q3T, Q3G, Q3A or Q3S were isolated from B*53 or B*81-expressing subjects. |
| Variant ID. | 3756 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPsDLNsML |
| Mutations | Q/S T/S |
| Epitope Location | Q3S T7S |
| HXB2 Location | Q182S T186S |
| Mutation Type | A: HLA association OV: observed variant |
| Epitope Subtype | B, C, D, F, G, J, K |
| Variant Subtype | C |
| Method | Other |
| Note | Variant TL9S3S7, TPsDLNsML, is present in 2.5% of B*81-/B*42- subjects; 28.6% of B*81+; and 14.3% of B*42+ subjects. |
| Variant ID. | 3757 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPaDLNTML |
| Mutations | Q/A |
| Epitope Location | Q3A |
| HXB2 Location | Q182A |
| Mutation Type | A: HLA association OV: observed variant |
| Epitope Subtype | B, C, D, F, G, J, K |
| Variant Subtype | C |
| Method | Other |
| Note | Variant, TPaDLNTML, is present in 7.1% of B*42+ subjects; 2.5% of B*42-/B*81- subjects. |
| Variant ID. | 3758 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPtDLNTML |
| Mutations | Q/T |
| Epitope Location | Q3T |
| HXB2 Location | Q182T |
| Mutation Type | A: HLA association OV: observed variant |
| Epitope Subtype | B, C, D, F, G, J, K |
| Variant Subtype | C |
| Method | Other |
| Note | Variant TL9T3, TPtDLNTML, is present in 28.6% of B*42+ subjects. |
| Variant ID. | 3759 |
|---|---|
| Epitope Seq. | TPQDLNTML |
| Variant Seq. | TPgDLNTML |
| Mutations | Q/G |
| Epitope Location | Q3G |
| HXB2 Location | Q182G |
| Mutation Type | A: HLA association OV: observed variant |
| Epitope Subtype | B, C, D, F, G, J, K |
| Variant Subtype | C |
| Method | Other |
| Note | Variant TPgDLNTML, is present in 7.1% of B*42+ subjects. |
Geldmacher2009 Christof Geldmacher, Ian S. Metzler, Sodsai Tovanabutra, Tedi E. Asher, Emma Gostick, David R. Ambrozak, Constantinos Petrovas, Alexandra Schuetz, Njabulo Ngwenyama, Gustavo Kijak, Leonard Maboko, Michael Hoelscher, Francine McCutchan, David A. Price, Daniel C. Douek, and Richard A. Koup. Minor Viral and Host Genetic Polymorphisms Can Dramatically Impact the Biologic Outcome of an Epitope-Specific CD8 T-Cell Response. Blood, 114(8):1553-1562, 20 Aug 2009. PubMed ID: 19542300. Show all entries for this paper.